

PRESENTER BIOGRAPHIES



SHELIA VIOLETTE, PHD is a scientific and industry leader in the field of inflammation, autoimmunity and fibrosis and Co-founder, Chief Scientific Officer and President of Research of Q32 *Bio*. She advanced Q32 *Bio* from a seed stage company and through Series B funding to become a clinical stage company with two programs in clinical development. In her more than 30 years of industry experience, she has provided strategic and operational leadership to multi-disciplinary teams of scientists, led several research and early clinical programs, and authored more than 100 manuscripts and patents. Prior to co-founding Q32 *Bio*, she was an Entrepreneur in Residence at *Atlas Venture* evaluating new company opportunities. Preceding her role at *Atlas*, Shelia served in leadership roles in the Immunology Research group at *Biogen*, joining *Stromedix* as Vice President of Research and returning to *Biogen* as Vice President of Research, spearheading the tissue injury and fibrosis therapeutic area. She also has directed research and led therapeutic programs at several biotechnology companies including *Repligen* and *Ariad*. She received her Ph.D. in Pharmacology from *Yale University*.



RHONDA WALLEN, MS, MBA is an Independent Board Director and Advisor specializing in life science companies. With over 25 years in the industry, she utilizes her expertise to assist CEOs and founders in strategy development, financing, and planning for execution and growth. Wallen's previous roles include Chief Strategy Officer / EVP of *Caresyntax* (providers of an end-to-end digital analytics platform for the surgical suite), Head of Global Corporate Development at *Terumo BCT* (the \$1 billion biomedical division of *Terumo Corporation*), and Chief Operating Officer of *Andarix Pharmaceuticals* (a clinical stage oncology therapeutics company). In consulting roles, she has also supported senior-level business development and marketing functions, assisting life science companies in defining key milestones and raising over \$30 million in corporate financing. As founding CEO of *Caveo Therapeutics*, a CU spin out company, she raised seed capital and launched a reagent product line, supporting the company's development of its lead oncology candidates. Wallen has a Bachelor of Science from *Stanford University*, a Master of Science in Microbiology, and a Master of Business Administration from the *University of Rochester*. Currently, she is an active member on the Board of Directors for *Ekso Bionics* (Medtech for stroke recovery and mobility enhancement), *Boulder Community Health* (\$500M hospital and ambulatory care system) and serves as a strategic Advisor for *A28 Therapeutics* (oncology), *Aromyx* (industrial biotech), and *ViuHealth* (healthcare data science).



KIMBERLY MULLER, ESQ. is the Executive Director of CU Innovations, leading innovation for the *University of Colorado Anschutz Medical Campus*. Her business development responsibilities include investing, company creation, innovation management, forming key strategic industry partnerships and licensing. Large-scale industry collaborations have been established in areas such as AI and drug development. She also manages several funds, including an innovation grant fund, and a nearly \$50 million venture fund. Kimberly was formerly the Deputy Director of the Yale Entrepreneurial Institute (YEI), managing New Ventures in the Office of Cooperative Research at *Yale University*. During her tenure, Yale's Office of Cooperative Research started 70+ new ventures that raised over \$5 billion in investor capital. Previously, she started and sold companies in the biotech, tech, and clean energy fields, companies included *Curagen Corporation* (acquired by *Celldex Therapeutics*), *454 Life Science* (acquired by *Roche*), and *Arbor Fuel*, a biofuel company that utilized recombinant microorganisms for the production of ethanol and butanol. Muller's career began in New York as a patent attorney for *Chadbourne and Parke, LLP*. Kimberly has a graduate degree in Genetics, and received her law degree with highest honors from the *University of Connecticut School of Law*.



DOREEN MOLK joined CU Innovations in May of 2017 as a licensing associate. She specializes in the marketing and licensing of innovative, high-impact technologies in order to transition them from the lab bench to the commercial market. Prior to joining the CU Innovations team, Molk was a licensing coordinator at the National Renewable Energy Laboratory, where she focused on the active marketing of technologies and management of NREL's diverse software portfolio. Doreen has also previously worked as a research assistant at the *University of Colorado* in the Department of Pediatric Hematology and Oncology as well as a teacher of high school biology. Doreen holds a Master of Science from the *Colorado School of Mines* in Applied Chemistry and a Bachelor of Arts from the *University of Colorado* in Biochemistry.

Note: Full bios can be viewed on the event website

WELCOME ATTENDEES!

AGENDA & PRESENTER INFORMATION

STORIES OF

WOMEN-LED INNOVATION

APR. 10
2023

CU ANSCHUTZ MEDICAL CAMPUS

Shattering the Glass Ceiling

APRIL 10, 2023 | 10AM-1PM | AHSB
DONALD M. ELLIMAN CONFERENCE CENTER

#WOMENLEDINNOVATION

**We strive to be inclusive and seek to include individuals who identify as transgender and non-binary. All genders are welcome!*

Hearing Impaired Compliant

SPONSORED BY:



Innovations

UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

CUANSCHUTZ.EDU/CU-INNOVATIONS

AGENDA

MONDAY,
APRIL 10, 2023

Shattering The Glass Ceiling: Stories of Women-Led Innovation

10:00 AM



SHOWCASE INTRODUCTION
DOREEN MOLK
Licensing Manager, CU Innovations, *CU Anschutz*

10:05-10:20 AM



DIGITAL HEALTH INNOVATOR
NEILL EPPERSON, MD
Professor & Chair, Department of Psychiatry, SOM, *CU Anschutz*

10:20-10:35 AM



THERAPEUTIC INNOVATOR
LESLIE LEINWAND, PHD
Chief Scientific Officer, BioFrontiers Institute, *CU Boulder* &
MCDB Distinguished Professor

10:35-10:50 AM



THERAPEUTIC INNOVATOR
VALERIA CANTO-SOLER, PHD
Associate Professor of Ophthalmology, SOM, *CU Anschutz*
Director, *Cellsight*

10:50-11:00 AM

10 MINUTE BREAK

11:00-11:15 AM



MEDICAL DEVICE INNOVATOR
HEATHER UNDERWOOD, PHD
Co-founder & Chief Executive Officer, *EvoEndo*

11:15-11:30 AM



MEDICAL DEVICE INNOVATOR
ROBIN DETERDING, MD
Medical Director, Center for Innovation, *Children's Hospital Colorado*
Co-founder, President & Chief Executive Officer, *Now Vitals*

11:30-11:45 AM



THERAPEUTIC INNOVATOR
SHELIA VIOLETTE, PHD
Co-founder, Chief Scientific Officer & President of Research, *Q32Bio*

11:45-NOON

15 MINUTE BREAK - LUNCH AVAILABLE WITH NAME BADGE

NOON-12:45 PM



PANEL DISCUSSION

Participants:
LESLIE LEINWAND, PHD, SHELIA VIOLETTE,
PHD & RHONDA WALLEN, MS, MBA

Moderator:
KIMBERLY MULLER, ESQ.
Executive Director, CU Innovations, *CU Anschutz*

12:45-1:30PM

NETWORKING LUNCHEON

PRESENTER BIOGRAPHIES



VALERIA CANTO-SOLER, PHD is an associate professor of Ophthalmology at the *University of Colorado Anschutz Medical Campus*. Her research focuses on two main, highly complementary areas: the mechanisms that control retinal progenitor cell differentiation and the use of human induced pluripotent stem cell (iPSC) technology to model normal and diseased conditions of the retina. Within this framework, her lab has recently established a strategy to direct hiPSC to differentiate into three-dimensional light-sensitive retinal tissue in vitro; she and her team are now using these retinal organoids to study the mechanisms underlying retinal degenerative diseases such as age-related macular degeneration (AMD), and to develop therapeutic treatments for these conditions. Dr. Canto-Soler is the Doni Solich Family Chair in Ocular Stem Cell Research and Director of *CellSight*. She completed her PhD in Biomedical Sciences at *Austral University* in Buenos Aires, Argentina and a postdoctoral fellowship at the Wilmer Eye Institute at *Johns Hopkins University* in Baltimore.



ROBIN DETERDING, MD is a renowned pediatric pulmonologist, executive healthcare administrator, and serial entrepreneur who is dedicated to transforming healthcare for children in Colorado and around the world. Currently, she serves as the Medical Director of the Center for Innovation at *Children's Hospital Colorado* and is the Co-founder, President and CEO of *Now Vitals*. With her experience as an entrepreneur who has founded three successful startups, including *EvoEndo*, *Earables*, and *Now Vitals*, she has advised organizations and evaluated over 100 companies for success. Dr. Deterding sees incredible potential for transformational disruption in healthcare and is committed to leading and inspiring diverse teams of talented individuals to create a better future through innovation, research, advocacy, education and exceptional clinical care. As the executive administrator of the largest breathing program in the country at *Children's Colorado*, Dr. Deterding is well-positioned to make a meaningful impact in healthcare.



NEILL EPPERSON, MD is the Robert Freedman Endowed Professor and Chair of the Department of Psychiatry in the School of Medicine at the *University of Colorado Anschutz Medical Campus*. Dr. Epperson is internationally known for her unique lifespan approach to women's reproductive and psychiatric health in both the clinical and research realms. Her research has been continuously funded for 25 years and by 5 of the NIH institute. Her body of work has led to a greater appreciation of the impact of childhood adversity on physiologic responses during times of hormonal fluctuation as well as gonadal steroid effects on brain and behavior. In addition to her role as Chair of Psychiatry, Dr. Epperson is the Executive Director of the Helen and Arthur E. Johnson Depression Center and Senior Scientific Advisor for the new center for innovations in psychiatry within the Department of Psychiatry. She has been the principal investigator on numerous academic-industry collaborations and is currently a key scientific leader in the collaboration between industry partner, *HealthRhythms*, CU Innovations and *UCHealth CARES Innovation Center*. Dr. Epperson is at the forefront of digital technology integration into clinical practice across the Department of Psychiatry.



LESLIE LEINWAND, PHD is a is a Molecular, Cellular and Developmental Biology (MCDB) Distinguished Professor and the Chief Scientific Officer of the *BioFrontiers Institute* at the University of Colorado Boulder. She received her Bachelor's degree from *Cornell University*, her PhD from *Yale University* and did post-doctoral training at *Rockefeller University*. She joined the faculty at *Albert Einstein College of Medicine* in New York in 1981 and remained there until moving to Colorado in 1995. She co-founded *Myogen, Inc.* which was sold to *Gilead Pharmaceuticals*. More recently, she was a co-founder of *Hiberna, Inc.*, and of *MyoKardia, Inc.*, a company founded to develop therapeutics for inherited cardiomyopathies. *MyoKardia* was acquired in 2020 by *Bristol Myers Squibb*.



HEATHER UNDERWOOD, PHD is the Co-founder and CEO of *EvoEndo*, a medical device company, with a decade of experience in the field. She has a highly interdisciplinary background in computer science, global health, human-centered design, education and international development. Heather is passionate about innovative ideas that lower costs, empower patients and physicians, improve health outcomes and make a meaningful impact on people's lives. Heather's experience includes co-founding *Inworks*, a *University of Colorado Denver* initiative, and being selected for the Stanford Biodesign Fellowship Class in 2018-2019. She has a Ph.D. from the *University of Colorado Boulder's ATLAS* program and a Bachelor of Science, cum laude, in computer science and engineering from the University of Washington. Currently, Heather is a member of the *Colorado Blackstone Entrepreneurs Network* and *Titan 100* program.

continued...